Format
Sort by

Send to

Choose Destination

Search results

Items: 17

1.

Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy.

Karampelas T, Skavatsou E, Argyros O, Fokas D, Tamvakopoulos C.

Mol Pharm. 2017 Feb 1. doi: 10.1021/acs.molpharmaceut.6b00961. [Epub ahead of print]

PMID:
28099809
2.

Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity.

Argyros O, Lougiakis N, Kouvari E, Papafotika A, Raptopoulou CP, Psycharis V, Christoforidis S, Pouli N, Marakos P, Tamvakopoulos C.

Eur J Med Chem. 2017 Jan 27;126:954-968. doi: 10.1016/j.ejmech.2016.12.025.

PMID:
28006668
3.

Discovery of new aminosubstituted pyrrolopyrimidines with antiproliferative activity against breast cancer cells and investigation of their effect towards the PI3Kα enzyme.

Daniilides K, Lougiakis N, Evangelidis T, Kostakis IK, Pouli N, Marakos P, Mikros E, Skaltsounis AL, Bach S, Baratte B, Ruchaud S, Karamani V, Papafotika A, Christoforidis S, Argyros O, Kouvari E, Tamvakopoulos C.

Anticancer Agents Med Chem. 2016 Dec 7. [Epub ahead of print]

PMID:
27928955
4.

Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.

Argyros O, Karampelas T, Asvos X, Varela A, Sayyad N, Papakyriakou A, Davos CH, Tzakos AG, Fokas D, Tamvakopoulos C.

Cancer Res. 2016 Mar 1;76(5):1181-92. doi: 10.1158/0008-5472.CAN-15-2138.

PMID:
26645560
5.

Sustained expression from DNA vectors.

Wong SP, Argyros O, Harbottle RP.

Adv Genet. 2015;89:113-52. doi: 10.1016/bs.adgen.2014.11.002. Review.

PMID:
25620010
6.

GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery.

Karampelas T, Argyros O, Sayyad N, Spyridaki K, Pappas C, Morgan K, Kolios G, Millar RP, Liapakis G, Tzakos AG, Fokas D, Tamvakopoulos C.

Bioconjug Chem. 2014 Apr 16;25(4):813-23. doi: 10.1021/bc500081g.

PMID:
24661240
7.

Examination of the effect of increasing the number of intra-disulfide amino functional groups on the performance of small molecule cyclic polyamine disulfide vectors.

Drake CR, Aissaoui A, Argyros O, Thanou M, Steinke JH, Miller AD.

J Control Release. 2013 Oct 10;171(1):81-90. doi: 10.1016/j.jconrel.2013.02.014.

PMID:
23454113
8.

Genetic modification of cancer cells using non-viral, episomal S/MAR vectors for in vivo tumour modelling.

Argyros O, Wong SP, Gowers K, Harbottle RP.

PLoS One. 2012;7(10):e47920. doi: 10.1371/journal.pone.0047920.

9.

Vector systems for prenatal gene therapy: principles of non-viral vector design and production.

Wong SP, Argyros O, Harbottle RP.

Methods Mol Biol. 2012;891:133-67. doi: 10.1007/978-1-61779-873-3_7.

PMID:
22648771
10.

Non-viral episomal modification of cells using S/MAR elements.

Argyros O, Wong SP, Harbottle RP.

Expert Opin Biol Ther. 2011 Sep;11(9):1177-91. doi: 10.1517/14712598.2011.582035. Review.

PMID:
21548848
11.

Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver.

Argyros O, Wong SP, Fedonidis C, Tolmachov O, Waddington SN, Howe SJ, Niceta M, Coutelle C, Harbottle RP.

J Mol Med (Berl). 2011 May;89(5):515-29. doi: 10.1007/s00109-010-0713-3.

PMID:
21301798
12.

Systemic gene transfer of polyethylenimine (PEI)-plasmid DNA complexes to neonatal mice.

Wong SP, Argyros O, Howe SJ, Harbottle RP.

J Control Release. 2011 Mar 30;150(3):298-306. doi: 10.1016/j.jconrel.2010.12.010.

PMID:
21192993
13.

Bioresponsive small molecule polyamines as noncytotoxic alternative to polyethylenimine.

Drake CR, Aissaoui A, Argyros O, Serginson JM, Monnery BD, Thanou M, Steinke JH, Miller AD.

Mol Pharm. 2010 Dec 6;7(6):2040-55. doi: 10.1021/mp9002249.

PMID:
20929266
14.

Non-viral S/MAR vectors replicate episomally in vivo when provided with a selective advantage.

Wong SP, Argyros O, Coutelle C, Harbottle RP.

Gene Ther. 2011 Jan;18(1):82-7. doi: 10.1038/gt.2010.116.

PMID:
20739959
15.

pEPito: a significantly improved non-viral episomal expression vector for mammalian cells.

Haase R, Argyros O, Wong SP, Harbottle RP, Lipps HJ, Ogris M, Magnusson T, Vizoso Pinto MG, Haas J, Baiker A.

BMC Biotechnol. 2010 Mar 15;10:20. doi: 10.1186/1472-6750-10-20.

16.

Strategies for the episomal modification of cells.

Wong SP, Argyros O, Coutelle C, Harbottle RP.

Curr Opin Mol Ther. 2009 Aug;11(4):433-41. Review.

PMID:
19649988
17.

Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector.

Argyros O, Wong SP, Niceta M, Waddington SN, Howe SJ, Coutelle C, Miller AD, Harbottle RP.

Gene Ther. 2008 Dec;15(24):1593-605. doi: 10.1038/gt.2008.113.

PMID:
18633447
Items per page

Supplemental Content

Loading ...
Support Center